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of Pulmonary Hypertension*
Enrique Calvo, PHD, Ana García-Álvarez, MD, PHD, Jesús Vázquez, PHDP ulmonary hypertension (PH) and subsequentright ventricular (RV) failure are increasinglyrecognized as global health problems,
affecting patients with highly prevalent diseases
such as chronic heart failure, chronic obstructive pul-
monary disease, collagen vascular disease, or chronic
pulmonary embolism (1). Regardless of the etiology,
PH has a poor prognosis, closely related to the degree
of RV functional impairment. There is therefore a
need to identify new tools allowing timely diagnosis
of PH and early detection of RV damage.
Recent evidence from in vitro and animal models
has revealed that the pathogenesis of PH may involve
metabolic reprogramming, including impaired glucose
homeostasis and alteredmitochondrialmetabolism. In
addition, clinical studies have revealed alterations to
the arginine-NO pathway in lung tissue from a
small cohort of patients with advanced PH (2) and in
plasma from patients with systolic heart failure and
increased pulmonary artery pressure (PAP) (3). These
ﬁndings suggest that these metabolic alterations
may track disease development, highlighting the po-
tential of circulating metabolites as PH biomarkers.
However, to date, there have been no published
metabolomic studies of plasma from patients with PH.SEE PAGE 174In this issue of the Journal, Lewis et al. (4) reported
on the search for plasma metabolite biomarkers of PH
and associated RV–pulmonary vasculature (PV)
dysfunction. Rather than using a discovery cohort
of individuals with or without known PH, the*Editorials published in the Journal of the American College of Cardiology
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relevant to the contents of this paper to disclose.investigators initially worked with 71 individuals with
dyspnea. Study participants were subjected to simul-
taneous invasive hemodynamic measurements, blood
sampling, and radionuclide ventriculography at rest
and during cardiopulmonary exercise testing. Five
hemodynamic parameters were correlated with the
concentration of 105 pre-selected plasma metabolites,
analyzed on a targeted proﬁling platform. Regression
analysis of the resulting 5  105 matrix identiﬁed 21
metabolites signiﬁcantly associated with 2 or more
RV-PV dysfunction parameters. A large fraction of
these metabolites belong to categories linked to PH in
earlier studies, including purine degradation products
and arginine and related metabolites. The increase in
the concentration of uric acid and other purine
metabolites is not surprising because uric acid is
associated with several cardiovascular and related
disorders, including hypertension, hypertrophy,
metabolic syndrome, and diabetes mellitus. More-
over, as the investigators indicated, purine metabo-
lites are linked to oxidative stress conditions.
Regarding arginine metabolites, the researchers found
a particularly strong inverse correlation between
overall arginine bioavailability (the ratio of arginine to
ornithine þ citrulline) and the change in mean PAP
relative to the change in cardiac output, apparently
reﬂecting a deﬁciency in NO-mediated vasodilation.
Diminished arginine bioavailability is observed in
many other end-organ dysfunctions linked to vascular
impairment, including renal failure and diabetes
mellitus. Therefore, this ﬁnding likely reﬂects the
generic importance of the production and balance of
NO for the maintenance of RV-PV function.
The study revealed a direct correlation between
RV-PV hemodynamic parameters and tricarboxylic
acid (TCA) cycle intermediates. Although this ﬁnding
was not explored further, the researchers discussed
the possibility that these intermediates may play a
role in modulating vascular tone in humans. Although
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191this intriguing hypothesis is supported by previous
evidence that succinate and other TCA intermediates
can act as signaling molecules through binding to
speciﬁc receptors, further studies are required to
clarify whether TCA intermediates elicit a compen-
satory mechanism to maintain blood pressure or are
byproducts produced by alterations to mitochondrial
metabolism (5).
The most remarkable ﬁnding of the present anal-
ysis is that RV-PV hemodynamic parameters showed
a strong direct correlation with a subset of tryptophan
metabolites. This subset did not include metabolites
of the tryptophan hydroxylase–mediated path-
way (leading to serotonin production). Instead, a
striking correlation was found with the levels of
the 4 tryptophan metabolites of the indoleamine
2,3-dioxygenase (IDO) pathway: kynurenine, kynur-
enate, anthranilate, and quinolinate. This ﬁnding is
particularly interesting because although the enzyme
IDO is known to be modulated by proinﬂammatory
cytokines and a growing body of evidence has indi-
cated that its byproduct kynurenine plays a role as
vasodilator (6), the tryptophan/IDO pathway had
never been associated with PH in humans. The in-
vestigators explored the speciﬁcity of the association
of the IDO pathway with pulmonary dysfunction in
2 elegant experiments. The ﬁrst analyzed the relative
concentrations of the 4 IDO metabolites in radial
and proximal pulmonary arteries. This experiment
revealed signiﬁcantly higher levels of the metabolites
in the radial artery of individuals with elevated pul-
monary vascular resistance (PVR), providing evidence
that these metabolites are produced in the lung. In
the second experiment, a mouse model of hypoxia-
induced PH showed upregulated mRNA levels of
IDO and elevated kynurenine/tryptophan ratios in
lung, as well as increased levels of IDO metabolites in
plasma. These results ﬁt nicely with an earlier report
showing that endogenous IDO expression by pulmo-
nary endothelium in a mouse model protected against
PH development (7). Based on these ﬁndings, Lewis
et al. (4) proposed that IDO metabolites are released
as vasodilators in response to PH, acting as a
compensatory pathway in states of NO deﬁciency.
This intriguing hypothesis raises the question of
whether this mechanism is speciﬁc to the pulmonary
arteries because IDO is also expressed in other
tissues.
The biomarker potential of the 4 IDO metabolites
was tested in a validation cohort composed of 71
individuals, studied similarly to the discovery cohort.
This analysis conﬁrmed a signiﬁcant association
of the IDO pathway with RV-PV dysfunction andshowed that IDO metabolites can discriminate be-
tween the absence or presence of abnormal pulmo-
nary vascular function (C-statistic >0.66). It should
be noted that the threshold used to deﬁne the pres-
ence of abnormal function (PVR >2.0 Wood units or
mean PAP >21 mm Hg) corresponds to “borderline
PH”; the clinical relevance of this threshold is still
undetermined, and it lies below the currently rec-
ommended threshold (PVR >3.0 Wood units and
mean PAP >25 mm Hg) (1).
The investigators also analyzed a second validation
cohort composed of 19 controls and 11 patients with
known World Health Organization group 1 pulmonary
artery hypertension. Three of the IDO metabolites
showed a strong ability to discriminate between the 2
groups (C-statistic >0.79). These are impressive re-
sults, but the small population size means that these
promising data are still preliminary. Conﬁrmation of
the clinical utility of IDO metabolites as PH bio-
markers will require analysis in larger cohorts. Simi-
larly, whether the IDO pathway could constitute a
therapeutic target in PH is unknown.
Another limitation of this study is the use of a
targeted conﬁguration, in which the set of metabo-
lites analyzed was pre-deﬁned. Compared with the
nontargeted, or shotgun, method, the targeted
approach is more straightforward, sensitive, and
systematic. However, it comes at the cost of produc-
ing potentially hypothesis-driven results because the
small number of target metabolites covers only a tiny
proportion of the estimated human endogenous
metabolome (more than 3,000 compounds), and se-
lection is inevitably inﬂuenced by prior knowledge of
the disease. Despite these limitations, the impressive
data gathered by Lewis et al. (4) show the remarkable
ability of metabolomics to identify intermediates
with important roles in PH. We foresee that
continuing improvements in mass spectrometry and
the expansion of compound libraries will allow the
development of novel approaches that combine the
wide coverage of shotgun analysis with the advan-
tages of targeted approaches, as is already happening
in the proteomics ﬁeld. These novel strategies would
move the ﬁeld toward a true metabolome-wide anal-
ysis, allowing full integration of phenotype and omics
data in the study of disease.
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